Orsted considers €5 billion rights offering to strengthen finances - Bloomberg
WEXFORD, Pa. and PRINCETON, N.J. - SNAP Biosciences, Inc., a subsidiary of Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP), a small-cap biotech company valued at $32.29 million, has entered into a licensing agreement with Monarch Therapeutics Inc. to further develop and commercialize its Snap-Car NK cell therapy platform for oncology treatments. According to InvestingPro analysis, COEP’s stock has shown remarkable momentum with a 134% surge over the past six months. The partnership, announced today, leverages Monarch’s small molecule adaptor technology to enhance the precision and flexibility of SNAP Biosciences’ cancer therapies.
The collaboration aims to address the challenges of tumor heterogeneity and antigen escape in oncology by engineering therapies that can target multiple tumor antigens and modulate activity in real-time. This could potentially lead to more effective treatments for patients with difficult-to-treat cancers. While the company maintains a moderate debt level, InvestingPro data indicates current short-term obligations exceed liquid assets, with a current ratio of 0.82.
Under the terms of the agreement, Monarch will receive an upfront licensing payment, with additional development milestone payments and royalties on net sales to follow. The financial details of the transaction were not disclosed.
Monarch’s scientific co-founders, Drs. Jason Lohmueller and Alexander Deiters, are credited with the invention of the small molecule adaptor-based technology platform that will now be integrated into SNAP Biosciences’ Snap-Car universal CAR-based receptor platform.
Christopher Potts, CEO of Monarch Therapeutics, expressed optimism about the partnership, highlighting the potential of the adaptor technology to transform cell therapy. Dave Mehalick, CEO at Coeptis Therapeutics Holdings, also conveyed enthusiasm for incorporating the innovative technology into their Snap-Car NK platform, emphasizing the potential advancements in NK therapies.
Monarch Therapeutics is a pre-clinical stage biotech company specializing in next-generation immunotherapies, while SNAP Biosciences focuses on developing "universal" CAR cell therapies for cancer treatment. Despite reporting negative EBITDA of -$10.14 million in the last twelve months, InvestingPro analysis suggests the company maintains a FAIR overall financial health score. Subscribers can access 10+ additional ProTips and detailed financial metrics to better evaluate COEP’s investment potential.
This article is based on a press release statement.
In other recent news, Coeptis, Inc. has launched a new technology hub in India in collaboration with NexGenAI Solutions Group and Ishvara Tech Consulting LLP. This strategic move aims to enhance the company’s capabilities in artificial intelligence and blockchain technology, with the facility focusing on research and development in these areas. Additionally, Coeptis announced the formation of a new subsidiary, GEAR Therapeutics, Inc., to advance a novel cell therapy platform for cancer treatment. This platform, acquired from VyGen-Bio, Inc., is designed to improve the efficacy of natural killer cells in cancer therapy by making them resistant to neutralization by monoclonal antibodies. In another development, Coeptis announced the departure of its Chief Scientific and Medical Officer, Colleen Delaney, who will continue to provide consulting services during a transition period. The company has not yet named a successor for Delaney. These announcements reflect Coeptis’ ongoing efforts to expand its technological and therapeutic capabilities in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.